DrugBank ID
stringlengths 7
7
| Accession Numbers
stringlengths 7
102
⌀ | Common name
stringlengths 3
226
| CAS
stringlengths 7
12
⌀ | UNII
stringlengths 10
10
⌀ | Synonyms
stringlengths 2
1.48k
⌀ | Standard InChI Key
stringlengths 27
27
⌀ |
|---|---|---|---|---|---|---|
DB18093
| null |
KIT-13
|
103628-72-4
|
6B7M56U62N
|
1-o-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine
|
LRBBGQHIVCMVRY-PQNGYSQDSA-N
|
DB18094
| null |
AMB-301
| null | null | null | null |
DB18095
| null |
Edralbrutinib
|
1858206-58-2
|
SG5I5QTR4E
|
4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7h-pyrrolo(2,3-d)pyridazin-7-one | 7h-pyrrolo(2,3-d)pyridazin-7-one, 4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)- | Edralbrutinib
|
DNPOFZXZJJDQLB-MRXNPFEDSA-N
|
DB18096
| null |
Encaleret
|
787583-71-5
|
EF8081AQ6G
|
(1,1'-biphenyl)-4-carboxylic acid, 2'-((1r)-1-((2r)-3-((2-(4-chloro-3-fluorophenyl)-1,1-dimethylethyl)amino)-2-hydroxypropoxy)ethyl)-3-methyl- | 2'-((1r)-1-(((1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl)amino)-(2r)-2-hydroxypropoxy)ethyl)-3-methyl(1,1'-biphenyl)-4-carboxylic acid | 2'-((1r)-1-(((2r)-3-((1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl)amino)-2-hydroxypropyl)oxy)ethyl)-3-methyl-1,1'-biphenyl-4-carboxylic acid | 2'-((1r)-1-((2r)-3-((1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl)amino)-2-hydroxypropoxy)ethyl)-3-methyl(1,1'-biphenyl)-4-carboxylic acid | Encaleret
|
UNFHDRVFEQPUEL-DENIHFKCSA-N
|
DB18097
| null |
(-)-beta-Elemene
|
515-13-9
|
2QG8CX6LXD
|
.beta.-elemene | (-)-.beta.-elemene | (-)-B-elemene | (-)-beta-Elemene | Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1s,2s,4r)- | Elemene, (-)-.beta.-
|
OPFTUNCRGUEPRZ-QLFBSQMISA-N
|
DB18098
| null |
Misetionamide
|
856785-75-6
|
489TQ24FC1
|
1,4Lambda6, 3-Oxathiazinane-4,4-dione
|
GHDARLKSYBCZRE-UHFFFAOYSA-N
|
DB18099
| null |
NX001
| null | null | null | null |
DB18100
| null |
Epeleuton
|
1667760-39-5
|
FA9BPX1T6V
|
15(s)-hydroxy-(5z,8z,11z,13e,17z)-eicosapentaenoic acid ethyl ester | 5,8,11,13,17-eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5z,8z,11z,13e,15s,17z)-
|
DJYKWMOPVZGTRJ-PILRRHKESA-N
|
DB18101
| null |
BZ371A
| null | null | null | null |
DB18102
| null |
Nedometinib
|
2252314-46-6
|
K5T4I78IYZ
|
2-((2-fluoro-4-iodophenyl)amino)-n-(2-hydroxyethoxy)-1-methyl-1h-pyrrolo(2,3-b)pyridine-3-carboxamide
|
SENAOZROGSYRTD-UHFFFAOYSA-N
|
DB18103
| null |
SPG302
|
2274723-90-7
|
CMJ4GT6MRD
|
2-(2-(2-(2-(4-benzothiazol-2-y1-phenoxy)-ethoxy)-ethoxy)-ethoxy)-ethanol | Ethanol, 2-(2-(2-(2-(4-(2-benzothiazolyl)phenoxy)ethoxy)ethoxy)ethoxy)-
|
XSAIPEACQNRHOL-UHFFFAOYSA-N
|
DB18104
| null |
TP-1287
|
2044686-42-0
|
7MPP85IIJ3
|
2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4-oxo-4H-chromen-7-yl dihydrogen phosphate | 4h-1-benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-((3s,4r)-3-hydroxy-1-methyl-4-piperidinyl)-7-(phosphonooxy)-
|
YRNFLVUMZIRYKY-BLLLJJGKSA-N
|
DB18105
| null |
BG-P-TAT
| null | null |
2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid
| null |
DB18106
| null |
Icapamespib
|
1000999-96-1
|
447591A1PU
|
9h-purine-9-ethanamine, 6-amino-n-(2,2-dimethylpropyl)-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-
|
UYODNJZBUUEXPC-UHFFFAOYSA-N
|
DB18107
| null |
SEL120-34A free base
|
1609522-33-9
|
6LGR0RYY5Q
|
4h-imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)- | 7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO(4,5,1-IJ)QUINOLINE | Cdk8-in-2 free base
|
FSBMCTDYWXIBLM-UHFFFAOYSA-N
|
DB18108
| null |
TQS-168
|
49671-76-3
|
3WT26285WB
|
2-(4-Tert-butylphenyl)-1H-benzimidazole
|
LQUNNCQSFFKSSK-UHFFFAOYSA-N
|
DB18109
| null |
TP-3654
|
1361951-15-6
|
EOB0N7BOY4
|
2-(4-((3-(3-(trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol | 2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin6-yl)amino)cyclohexyl)propan-2-ol hydrochloride | 4-((3-(3-(trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol
|
XRNVABDYQLHODA-JCNLHEQBSA-N
|
DB18110
| null |
Nesuparib
|
2055357-64-5
|
U6N7333GDW
|
6-(4-((5-oxo-1,2,3,4,5,6-hexahydrobenzo(h)(1,6)naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile
|
GRPXLKXGJAGYSD-UHFFFAOYSA-N
|
DB18111
| null |
Berberine ursodeoxycholate
|
1868138-66-2
|
VM8KQ3W8GM
|
9,10-dimethoxy-5,6-dihydro-2H,8H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-ylium 3α,7β-dihydroxy-5β-cholan-24-oate | Cholan-24-oic acid, 3,7-dihydroxy-, ion(1-), (3α,5β,7β)-, 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium (1:1)
|
FHZVFXJRSFLYDY-FUXQPCDDSA-M
|
DB18112
| null |
NT-102
|
1607447-79-9
|
CL92X4LP4N
|
2-[(3-Methylbutyl)amino]-1,4-naphthalenedione
|
JLOBMWCZCWALTQ-UHFFFAOYSA-N
|
DB18113
| null |
7.beta.-hydroxycholesteryl-3-oleate
|
141099-60-7
|
A59FMD985O
|
7.beta.-hydroxycholesterol 3-oleate | 7.beta.-hydroxycholesteryl 3-oleate | Cholest-5-ene-3,7-diol, 3-(9z)-9-octadecenoate, (3.beta.,7.beta.)-
|
MEOFSGIGKMJGOJ-FTKDFQSGSA-N
|
DB18114
| null |
AUM-302
|
1414455-21-2
|
F7WQK85U32
|
19H-22,25-Epithio-4,6:7,11:14,18-trimetheno-12H-pyrimido[5,4-j][1,9,2,5,17]dithiatriazacyclotricosin-19-one, 17-fluoro-20,21-dihydro-10-methoxy-29-methyl-, 13,13-dioxide
|
WHJIHZSXTQRCNX-UHFFFAOYSA-N
|
DB18115
| null |
Golcadomide
|
2379572-34-4
|
29HLR8Z5BR
|
2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione
|
NZYDBVQXOGPDDU-QHCPKHFHSA-N
|
DB18116
| null |
PLG-0206
|
847061-43-2
|
C8ECW4KP2L
| null | null |
DB18117
| null |
2'-deoxythioguanosine
|
789-61-7
|
KR0RFB46DF
|
2-amino-9-(2-deoxy-.beta.-d-erythro-pentofuranosyl)-6-mercaptopurine | 2'-deoxy-6-thioguanosine | 2'-desoxy-6-thioguanosine | Beta-2'-deoxythioguanosine | Thioguanine deoxyriboside
|
SCVJRXQHFJXZFZ-KVQBGUIXSA-N
|
DB18118
| null |
6-fluoro-9-methyl-9H-pyrido(3,4-B)-indole
| null |
KT2RT2HH65
|
6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole
|
ZKCQFUOLWYLCFK-UHFFFAOYSA-N
|
DB18119
| null |
SXR-1096
|
1087624-28-9
|
BDQ30W2KTS
|
4h-3,1-benzoxazin-4-one, 6-ethoxy-7-methoxy-2-(2-(methylthio)phenyl)- | 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one
|
JTQBMTFVGGUDPN-UHFFFAOYSA-N
|
DB18120
| null |
EP-0042
|
1402709-93-6
|
ZE94SP78UG
|
3H-IMIDAZO(4,5-B)PYRIDINE, 6-CHLORO-7-(4-((4-CHLOROPHENYL)METHYL)-1-PIPERAZINYL)-2-(1,3-DIMETHYL-1H-PYRAZOL-4-YL)-
|
AKJBLKUZXRMECW-UHFFFAOYSA-N
|
DB18121
| null |
YA-101
|
151602-49-2
| null |
1h-benzimidazol-6-ol, 2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- | 2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol | 5-o-desmethyl omeprazole | 5-o-desmethylomeprazole
| null |
DB18122
| null |
PF-07059013
|
2435610-93-6
|
FXK42BP3GL
|
2(1h)-pyridinone, 6-((1s)-1-((2-amino-6-fluoro-3-quinolinyl)oxy)ethyl)-5-(1h-pyrazol-1-yl)- | 6-((1s)-1-((2-amino-6-fluoroquinolin-3-yl)oxy)ethyl)-5-(1h-pyrazol-1-yl)pyridin-2(1h)-one
|
CLEFVPILGAPOTG-NSHDSACASA-N
|
DB18123
| null |
PHE885
| null | null | null | null |
DB18124
| null |
Fipaxalparant
|
1195941-38-8
|
Y76WZ464EY
|
1h-indene-2-carboxylic acid, 2,3-dihydro-2-((4-methoxy-3-(2-(3-methylphenyl)ethoxy)benzoyl)amino)-
|
SOJDTNUCCXWTMG-UHFFFAOYSA-N
|
DB18125
| null |
PTX-100
|
501010-06-6
|
M67G28K74K
|
2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid | GGTI-2418
|
COLCNDRDBCLVOC-ICSRJNTNSA-N
|
DB18126
| null |
Vipoglanstat
|
1360622-01-0
|
FN57BDR4DA
|
2-{2,6-Dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoroethoxy)-1-methyl-1H-benzoimidazole-5-carboxylic acid (trans-4-trifluoromethylcyclohexyl)-amide
|
PFORUFFGGNOLPJ-QAQDUYKDSA-N
|
DB18127
| null |
RGLS-8429
| null | null | null | null |
DB18128
| null |
Anti-CD7 CAR T-cell therapy
| null | null |
A chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7
| null |
DB18129
| null |
OTOF-GT
| null | null | null | null |
DB18130
| null |
DYNE-251
| null | null | null | null |
DB18131
| null |
NKX101
| null | null |
a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15)
| null |
DB18132
| null |
PMC-403
| null | null |
a fully human monoclonal antibody that binds and activates the Tie2 receptor
| null |
DB18133
| null |
ARGX-119
| null | null |
a fully humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and activates MuSK
| null |
DB18134
| null |
DS-2325a
| null | null | null | null |
DB18135
| null |
SGN-1
| null | null |
SalMet-Vec
| null |
DB18136
| null |
Briquilimab
|
2574591-89-0
|
QWX84D0DRC
|
IMMUNOGLOBULIN G1 (297-GLUTAMINE), ANTI-(HUMAN C-KIT RECEPTOR) (HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL JSP191 .KAPPA.-CHAIN, DIMER
| null |
DB18137
| null |
Xaluritamig
| null | null |
Immunoglobulin G1 Fab fragment [218-lysine], anti-(human metalloproteinase STEAP1) (human-Mus musculus clone 2F3.013 N67Q γ1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human CD3 antigen) (human-Mus muscul | immunoglobulin G1-scFv-CH/G1-kappa, anti-[Homo sapiens STEAP1 (STEAP family member 1, six transmembrane epithelial antigen of the prostate 1, STEAP1 metalloreductase) and anti-[Homo sapiens CD3, bispecific, trivalent
| null |
DB18138
| null |
PBKR03
| null | null | null | null |
DB18139
| null |
SBT101
| null | null | null | null |
DB18140
| null |
TN-401
| null | null |
A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene
| null |
DB18141
| null |
ATX-01
| null | null | null | null |
DB18142
| null |
BBT-059
| null | null | null | null |
DB18143
| null |
MTL-CEBPA
| null | null | null | null |
DB18144
| null |
Alidornase alfa
|
1788036-49-6
|
D4W5757EP4
|
Deoxyribonuclease (synthetic human), amide with 1,2-ethanediamine
| null |
DB18145
| null |
Aloxistatin
|
88321-09-9
|
L5W337AOUR
|
Ethyl (+)-(2s,3s)-2,3-epoxy-n-((s)-1-(isopentylcarbamoyl)-3-methylbutyl)succinamate | Loxistatin
|
SRVFFFJZQVENJC-IHRRRGAJSA-N
|
DB18146
| null |
Berbamine
|
478-61-5
|
V5KM4XJ0WM
|
(+)-berbamine | 16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolin-12-ol, 3,4,4a,5,16a,17,18,19-octahydro-21,22,26-trimethoxy-4,17-dimethyl-, (4as-(4ar*,16as*))- | 16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolin-12-ol, 3,4,4a,5,16a,17,18,19-octahydro-21,22,26-trimethoxy-4,17-dimethyl-, (4as,16ar)- | 6,6',7-trimethoxy-2,2'-dimethylberbaman-12-ol | Berbaman-12-ol, 6,6',7-trimethoxy-2,2'-dimethyl- | Berbamine, (+)- | Berbenine | D-berbamine
|
DFOCUWZXJBAUSQ-URLMMPGGSA-N
|
DB18147
| null |
Firolimogene autotemcel
| null |
XH2XT2GQS6
|
AUTOLOGOUS CD34+ CELLS ISOLATED FROM BONE MARROW OF NEWLY DIAGNOSED X-LINKED SEVERE COMBINED IMMUNODEFICIENCY (X-SCID) PATIENTS, TRANSDUCED EX VIVO WITH A SELF-INACTIVATING LENTIVIRAL VECTOR, ENCODING CODON-OPTIMIZED HUMAN INTERLEUKIN-2 RECEPTOR SUBUNIT
| null |
DB18148
| null |
Gentulizumab
| null | null |
GENTULIZUMAB (anti-CD47 Humanized Monoclonal Antibody)
| null |
DB18149
| null |
IK-930
| null | null | null | null |
DB18150
| null |
NRP-2945
| null | null | null | null |
DB18151
| null |
Mocravimod
|
509092-16-4
|
X71GCJ0HLI
|
1,3-propanediol, 2-amino-2-(2-(2-chloro-4-((3-(phenylmethoxy)phenyl)thio)phenyl)ethyl)- | 2-amino-2-(2-(2-chloro-4-(3-benzyloxyphenylthio)phenyl)ethyl)-1,3-propanediol | Krp-203 free base
|
IINUNQPYJGJCJI-UHFFFAOYSA-N
|
DB18152
| null |
Zilurgisertib
|
2173389-57-4
|
L5Z9S25HO2
| null |
KPRPFTOLWQQUAV-OCVAFRRMSA-N
|
DB18153
| null |
ENA-001
|
1380341-99-0
|
4RZ4OGT40Z
|
1,3,5-triazine-2,4,6-triamine, n2-methoxy-n2-methyl-n4,n6-dipropyl-
|
FJNLCHNQVJVCPY-UHFFFAOYSA-N
|
DB18154
| null |
Utreloxastat
|
1213269-96-5
|
WW8KZK2PZT
|
2,5-cyclohexadiene-1,4-dione, 2,3,5-trimethyl-6-nonyl-
|
IJWAQTHZBDBIID-UHFFFAOYSA-N
|
DB18155
| null |
ESK981
|
856691-93-5
|
J8AY0Z4CBP
|
4h-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-, 4-methylbenzenesulfonate (1:1) | Bol 303213x tosylate | Bol-303213x tosylate | Cep-11981 tosylate
|
OCCDXAYTEKPNMM-UHFFFAOYSA-N
|
DB18156
| null |
QN-302
|
2546091-70-5
|
86Y5JME9KT
|
2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-9-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone
|
JQXVCGMANURRRW-UHFFFAOYSA-N
|
DB18157
| null |
ABX-002
|
2156649-32-8
|
QTW4WC4BRX
|
2-(3,5-DICHLORO-4-((4-HYDROXY-3-(PROPAN-2-YL)PHENYL)METHYL)PHENOXY)-N-METHYLACETAMIDE
|
CQELSEDWYWTMDG-UHFFFAOYSA-N
|
DB18158
| null |
ION582
| null | null | null | null |
DB18159
| null |
Atesidorsen
|
872063-57-5
|
015582E098
| null | null |
DB18160
| null |
VO659
|
1479142-52-3
| null |
an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)
| null |
DB18161
| null |
Zilganersen
|
2305355-56-8
|
AXQ9493NT2
| null | null |
DB18162
| null |
ION283
| null | null | null | null |
DB18163
| null |
LipidRescue
| null | null | null | null |
DB18164
| null |
4-[211At]-L-phenylalanine
| null | null | null | null |
DB18165
| null |
ER2001
| null | null | null | null |
DB18166
| null |
AK-OTOF
| null | null | null | null |
DB18167
| null |
ANG1005
| null | null | null | null |
DB18168
| null |
SKL-27969
|
2634762-24-4
|
NVE35UH48R
| null | null |
DB18169
| null |
CP-12
| null |
SM5MFZ7FKP
|
CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK) | PROLYL-L-SERYL-L-HISTIDYL-L-ISOLEUCYL-L-SERYL-L-LYSYL-L-TYROSYL-L-ISOLEUCYL-L-LEUCYL- L-ARGINYL-L-TRYPTOPHANYL-L-ARGINYL-L-PROLYL-L-LYSYL), CYCLO (1-14)
|
IZEYWQHWXBTEIK-POJYALDXSA-N
|
DB18170
| null |
Cu-64 sartate
| null |
UJY48W6ADC
|
[64Cu]Cu-[MeCOSar0-Tyr3]-octreotate | 64CU SARTATE | CU-64 SARTATE | SARTATE CU-64 | UCASAREOTIDE DASAROXETAN CU-64
| null |
DB18171
| null |
KTX-1001
| null | null |
(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol
| null |
DB18172
| null |
BN104
| null | null |
(2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone
| null |
DB18173
| null |
BRG01
| null | null | null | null |
DB18174
| null |
JTT-251
|
1627957-25-8
|
VZ3FG834W3
| null |
KNPYQCPWTWANOG-RUZDIDTESA-N
|
DB18175
| null |
Ga-68 Trivehexin
| null | null |
(68-Ga)-Trivehexin
| null |
DB18176
| null |
Etavopivat
|
2245053-57-8
|
V4E0A9M44Q
|
1-propanone, 1-(5-((2,3-dihydro-1,4-dioxino(2,3-b)pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo(3,4-c)pyrrol-2(1h)-yl)-3-hydroxy-2-phenyl-, (2s)-
|
KZFFYEPYCVDOGE-LJQANCHMSA-N
|
DB18177
| null |
BNT111
| null | null | null | null |
DB18178
| null |
Flumecinol
|
56430-99-0
|
JB0YA8LDOW
|
.alpha.-ethyl-3-(trifluoromethyl)benzhydrol | (+/-)-flumecinol | 1-(3-trifluoromethylphenyl)-1-phenylpropan-1-ol | 3-(trifluoromethyl)-.alpha.-ethylbenzhydrol | Benzenemethanol, .alpha.-ethyl-.alpha.-phenyl-3-(trifluoromethyl)- | Zyxorin
|
DVASNQYQOZHAJN-UHFFFAOYSA-N
|
DB18179
| null |
LYT-200
| null | null | null | null |
DB18180
| null |
CT103A
| null | null | null | null |
DB18181
| null |
CT120
| null | null | null | null |
DB18182
| null |
Ersodetug
|
2410976-61-1
|
QD87BSP58N
|
gamma2 heavy chain Homo sapiens (1-444) [VH(Homo sapiens IGHV3-20*01 (98.0%) -(IGHD)-IGHJ6*01 (93.8%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG2*02 (100%), G2m23 CH2 M45.1 (CH1 (119-216), hinge 1-12 (217-228), CH2 M45.1 (279) (2 | immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric | Immunoglobulin G2, anti-(human insulin receptor) (human monoclonal RZ358 γ2-chain), disulfide with human monoclonal RZ358 κ-chain, dimer
| null |
DB18183
| null |
NBL-015
| null | null |
Fully human monoclonal IgG1 antibody against the type 2 isoform of human Claudin 18 protein (Claudin 18.2). | NBL-015 (ANTI-CLAUDIN18.2 MAB)
| null |
DB18184
| null |
ZYIL-1
|
2455519-86-3
|
P9ZQS28F8C
| null |
HAMGPBKPACGWND-ZOXUKVPXSA-N
|
DB18185
| null |
ATI-1013
| null | null |
Fully human nicotine-specific monoclonal antibody
| null |
DB18186
| null |
BMN-351
| null | null | null | null |
DB18187
| null |
Nemvaleukin alfa
|
2315268-27-8
|
7ZX1Q9SJ1F
|
75-133-interleukin 2 (125-serine) (human) fusion protein with peptide linker (gg) fusion protein with 4-74-interleukin 2 (human) fusion protein with peptide linker (gsgggs) fusion protein with 1-165-interleukin 2 receptor .alpha.-chain (human) | 75-133-Interleukin 2 [125-serine] (human) fusion protein with peptide linker (GG) fusion protein with 4-74-interleukin 2 (human) fusion protein with peptide linker (GSGGGS) fusion protein with 1-165-interleukin 2 receptor α-chain (human) | Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha | human interleukin 2 fragment (1-59), variant (Cys125>Ser51), fused via peptidyl linker (60GG61) to human interleukin 2 fragment (62-132), fused via peptidyl linker (133GSGGGS138) to human interleukin 2 receptor α-chain fragment (139-303), produced in Ch
| null |
DB18188
| null |
EDI-200
| null |
AF6GZK1UMB
|
FC:EDA-A1 FUSION PROTEIN | HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN
| null |
DB18189
| null |
AGuIX
| null | null | null | null |
DB18190
| null |
Dotatoc gallium Ga-68
|
1040397-47-4
|
8AHG0Z4Z5M
|
(68ga)-dotanoc | 68-ga-dotanoc | Dota-nal3-octreotide Ga-68 | Dotanoc gallium Ga-68
|
WLCSPWJAQXJSCS-LMLQMHQSSA-K
|
DB18191
| null |
Gunagratinib
|
2211082-53-8
|
9D589FD91A
|
(s)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1h-pyrazole-4-carboxamide | 1h-pyrazole-4-carboxamide, 3-(2-(3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1-((3s)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)-
|
QFUIJOBJAQBGDH-HNNXBMFYSA-N
|
DB18192
| null |
CLBS12
| null | null | null | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.